Last reviewed · How we verify
Adenuric
Adenuric is a Small molecule drug developed by Pharmtechnology LLC. It is currently in Phase 3 development for Gout Prevention, Hyperuricemia. Also known as: the reference product.
Adenuric, also known as Febuxostat, is a medication used to treat gout due to high uric acid levels. It is typically taken orally and is recommended for people who cannot take allopurinol.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Adenuric |
|---|---|
| Also known as | the reference product |
| Sponsor | Pharmtechnology LLC |
| Target | Flavin reductase (NADPH), ATP-binding cassette sub-family G member 2, Potassium voltage-gated channel subfamily H member 2 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
- Gout Prevention
- Hyperuricemia
Common side effects
Key clinical trials
- Immediate Prescription of a Hypouricemic Treatment, Febuxostat, Compared to Its Delayed Administration (PHASE3)
- Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults (PHASE1, PHASE2)
- Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients (PHASE2)
- Role of Uralyt-U in Patients With Hyperuricemia (NA)
- Uric Acid Effects on Endothelium and Oxydative Stress (NA)
- Compare the Renal Protective Effects of Febuxostat and Benzbromarone (NA)
- Bioequivalence Study of Two Formulations of Febuxostat 120 mg Film-coated Tablets in Healthy Adult Volunteers After a Single Oral Dose Administration Under Fasting Conditions (PHASE1)
- Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adenuric CI brief — competitive landscape report
- Adenuric updates RSS · CI watch RSS
- Pharmtechnology LLC portfolio CI
Frequently asked questions about Adenuric
What is Adenuric?
What is Adenuric used for?
Who makes Adenuric?
Is Adenuric also known as anything else?
What development phase is Adenuric in?
What does Adenuric target?
Related
- Target: All drugs targeting Flavin reductase (NADPH), ATP-binding cassette sub-family G member 2, Potassium voltage-gated channel subfamily H member 2
- Manufacturer: Pharmtechnology LLC — full pipeline
- Therapeutic area: All drugs in Other
- Indication: Drugs for Gout Prevention
- Indication: Drugs for Hyperuricemia
- Also known as: the reference product
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing